Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Rare diseases, rare presentations, recognizing atypical inherited kidney disease phenotypes in the age of genomics

  • Ars, Elisabet|||0000-0002-4118-4358
  • Torra Balcells, Roser|||0000-0001-8714-2332
A significant percentage of adults (10%) and children (20%) on renal replacement therapy have an inherited kidney disease (IKD). The new genomic era, ushered in by the next generation sequencing techniques, has contributed to the identification of new genes and facilitated the genetic diagnosis of the highly heterogeneous IKDs. Consequently, it has also allowed the reclassification of diseases and has broadened the phenotypic spectrum of many classical IKDs. Various genetic, epigenetic and environmental factors may explain 'atypical' phenotypes. In this article, we examine different mechanisms that may contribute to phenotypic variability and also provide case examples that illustrate them. The aim of the article is to raise awareness, among nephrologists and geneticists, of rare presentations that IKDs may show, to facilitate diagnosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Recent advances in the clinical management of autosomal dominant polycystic kidney disease

  • Torra Balcells, Roser|||0000-0001-8714-2332
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic systemic disorder causing the development of renal and hepatic cysts and decline in renal function. It affects around 1 in 1,000 live births. Early hypertension and progressive renal failure due to massive enlargement of cysts and fibrosis are hallmarks of the disease. This article reviews recent advances in ADPKD and focuses mainly on diagnosis, management, and prediction of the course of the disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

How genomics reclassifies diseases, the case of Alport syndrome

  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Furlano, Monica|||0000-0003-1025-3901
  • Ars, Elisabet|||0000-0002-4118-4358
In this issue, Matthews et al. provide a comprehensive review of published cohorts with heterozygous pathogenic variants in COL4A3 or COL4A4, documenting the wide spectrum of the disease. Due to the extreme phenotypes that patients with heterozygous pathogenic variants in COL4A3 or COL4A4 may show, the disease has been referred to in a variety of ways, including 'autosomal dominant Alport syndrome', 'thin basement membrane disease', 'thin basement membrane nephropathy', 'familial benign hematuria' and 'carriers of autosomal dominant Alport syndrome'. This confusion over terminology has prevented nephrologists from being sufficiently aware of the relevance of the entity. Nowadays, however, next-generation sequencing facilitates the diagnosis and it is becoming a relatively frequent finding in haematuric-proteinuric nephropathies of unknown origin, even in non-familial cases. There is a need to raise awareness among nephrologists about the disease in order to improve diagnosis and provide better management for these patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease

  • Górriz, Jose Luis|||0000-0002-1134-9051
  • Arroyo, David|||0000-0003-4652-0311
  • D'Marco, Luis|||0000-0003-0148-891X
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Tomás, Patricia
  • Puchades, María Jesús
  • Panizo, Nayara|||0000-0002-1329-2976
  • Pantoja, Jonay
  • Montomoli, Marco|||0000-0003-1412-6352
  • Llisterri, José Luis
  • Pallarés Carratalá, Vicente|||0000-0002-2985-6078
  • Valdivielso, José Manuel|||0000-0003-1343-0184
Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent hereditary renal disease. There is an increased rate of cardiovascular disease (CVD) in ADPKD. In this study, we evaluate the prevalence of cardiovascular risk factors, the achievement rates for treatment goals and cardiovascular events (CVE) in ADPKD and their relations with asymptomatic CVD in CKD from other etiologies (CKDoe) and controls. We evaluated 2445 CKD patients (2010-2012). The information collected was: clinical, anthropometric and analytical parameters, treatments and CVD evaluation (intima-media thickness (IMT), atheromatous plaque presence and ankle-brachial index (ABI)). Laboratory, vital status, CVE and hospitalizations were collected for 4 years. ADPKD patients had a worse renal function and worst achievement of blood pressure, higher parathormone levels but lower proteinuria compared to CKDoe. ADPKD patients presented lower IMT values than other groups, however, an intermediate rate of pathologic ABI and atheromatous plaque was present. More than half of the patients received statins, achieving LDL-c levels < 100 only in 50 and 39.8% of them (ADPKD and CKDoe respectively). The number of CVE during the follow-up period was low. In adjusted Cox regression model, ADPDK had the lowest occurrence of CVE of all three groups (HR:0.422, 95%CI 0.221-0.808, p = 0.009). ADPKD patients show intermediate control rates of CVD. A better control of CVD risk seems to be related with a lower load of CVD compared to other groups, which may lead in the long term to a better prognosis. Further investigation is necessary to determine cardiovascular prognosis in ADPKD. The online version contains supplementary material available at 10.1186/s12882-021-02313-1.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The 2019 and 2021 International Workshops on Alport Syndrome

  • Daga, Sergio
  • Ding, Jie
  • Savige, Judy|||0000-0002-6813-0288
  • Lipska-Ziętkiewicz, Beata S.|||0000-0002-4169-9685
  • Hoefele, Julia|||0000-0002-7917-7129
  • Flinter, Frances
  • Gale, Daniel|||0000-0002-9170-1579
  • Aksenova, Marina|||0000-0002-3699-1884
  • Kai, Hirofumi
  • Perin, Laura
  • Barua, Moumita
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Miner, Jeff H.|||0000-0002-1510-8714
  • Massella, Laura|||0000-0001-5796-3965
  • Ljubanović, Danica Galešić
  • Lennon, Rachel|||0000-0001-6400-0227
  • Weinstock, Andrè B.
  • Knebelmann, Bertrand
  • Cerkauskaite, Agne
  • Gear, Susie
  • Gross, Oliver|||0000-0002-8390-8852
  • Turner, A. Neil|||0000-0003-4547-873X
  • Baldassarri, Margherita
  • Pinto, Anna Maria|||0000-0001-6259-6901
  • Renieri, Alessandra|||0000-0002-0846-9220
In 1927 Arthur Cecil Alport, a South African physician, described a British family with an inherited form of kidney disease that affected males more severely than females and was sometimes associated with hearing loss. In 1961, the eponymous name Alport syndrome was adopted. In the late twentieth century three genes responsible for the disease were discovered: COL4A3, COL4A4, and COL4A5 encoding for the α3, α4, α5 polypeptide chains of type IV collagen, respectively. These chains assemble to form heterotrimers of type IV collagen in the glomerular basement membrane. Scientists, clinicians, patient representatives and their families, and pharma companies attended the 2019 International Workshop on Alport Syndrome, held in Siena, Italy, from October 22 to 26, and the 2021 online Workshop from November 30 to December 4. The main topics included: disease re-naming, acknowledging the need to identify an appropriate term able to reflect considerable clinical variability; a strategy for increasing the molecular diagnostic rate; genotype-phenotype correlation from monogenic to digenic forms; new therapeutics and new therapeutic approaches; and gene therapy using gene editing. The exceptional collaborative climate that was established in the magical medieval setting of Siena continued in the online workshop of 2021. Conditions were established for collaborations between leading experts in the sector, including patients and drug companies, with the aim of identifying a cure for Alport syndrome.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical and Genetic Features of Autosomal Dominant Alport Syndrome, A Cohort Study

  • Furlano, Monica|||0000-0003-1025-3901
  • Martínez, Victor
  • Pybus, Marc|||0000-0002-6195-5738
  • Arce, Yolanda
  • Crespí, Jaume|||0000-0001-7564-2479
  • Venegas, María del Prado|||0000-0001-9048-4501
  • Bullich Vilanova, Gemma|||0000-0002-0737-4422
  • Domingo, Andrea|||0000-0003-3759-7595
  • Ayasreh Fierro, Nadia|||0000-0001-6436-5621
  • Benito, Silvia
  • Lorente, Laura
  • Ruíz, Patricia
  • Gonzalez, Vanesa L.
  • Arlandis, Rosa
  • Cabello, Elisa
  • Torres, Ferran|||0000-0002-7355-7913
  • Guirado, Luis|||0000-0001-5119-3912
  • Ars, Elisabet|||0000-0002-4118-4358
  • Torra Balcells, Roser|||0000-0001-8714-2332
Rationale & Objective: Alport syndrome is a common genetic kidney disease accounting for approximately 2% of patients receiving kidney replacement therapy (KRT). It is caused by pathogenic variants in the gene COL4A3, COL4A4, or COL4A5. The aim of this study was to evaluate the clinical and genetic spectrum of patients with autosomal dominant Alport syndrome (ADAS). Study Design: Retrospective cohort study. Setting & Participants: 82 families (252 patients) with ADAS were studied. Clinical, genetic, laboratory, and pathology data were collected. Observations: A pathogenic DNA variant in COL4A3 was identified in 107 patients (35 families), whereas 133 harbored a pathogenic variant in COL4A4 (43 families). Digenic/complex inheritance was observed in 12 patients. Overall, the median kidney survival was 67 (95% CI, 58-73) years, without significant differences across sex (P = 0.8), causative genes (P = 0.6), or type of variant (P = 0.9). Microhematuria was the most common kidney manifestation (92.1%), and extrarenal features were rare. Findings on kidney biopsies ranged from normal to focal segmental glomerulosclerosis. The slope of estimated glomerular filtration rate change was -1.46 (-1.66 to -1.26) mL/min/1.73 m per year for the overall group, with no significant differences between ADAS genes (P = 0.2). Limitations: The relatively small size of this series from a single country, potentially limiting generalizability. Conclusions: Patients with ADAS have a wide spectrum of clinical presentations, ranging from asymptomatic to kidney failure, a pattern not clearly related to the causative gene or type of variant. The diversity of ADAS phenotypes contributes to its underdiagnosis in clinical practice.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Genetic kidney diseases as an underrecognized cause of chronic kidney disease, the key role of international registry reports

  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Furlano, Monica|||0000-0003-1025-3901
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Ars, Elisabet|||0000-0002-4118-4358
Inherited kidney diseases (IKDs) are among the leading causes of early-onset chronic kidney disease (CKD) and are responsible for at least 10-15% of cases of kidney replacement therapy (KRT) in adults. Paediatric nephrologists are very aware of the high prevalence of IKDs among their patients, but this is not the case for adult nephrologists. Recent publications have demonstrated that monogenic diseases account for a significant percentage of adult cases of CKD. A substantial number of these patients have received a non-specific/incorrect diagnosis or a diagnosis of CKD of unknown aetiology, which precludes correct treatment, follow-up and genetic counselling. There are a number of reasons why genetic kidney diseases are difficult to diagnose in adulthood: (i) adult nephrologists, in general, are not knowledgeable about IKDs; (ii) existence of atypical phenotypes; (iii) genetic testing is not universally available; (iv) family history is not always available or may be negative; (v) lack of knowledge of various genotype-phenotype relationships and (vi) conflicting interpretation of the pathogenicity of many sequence variants. Registries can contribute to visualize the burden of IKDs by regularly grouping all IKDs in their annual reports, as is done for glomerulonephritis or interstitial diseases, rather than reporting only cystic disease and hiding other IKDs under labels such as 'miscellaneous' or 'other'. Any effort to reduce the percentage of patients needing KRT with a diagnosis of 'nephropathy of unknown etiology' or an unspecific/incorrect diagnosis should be encouraged as a step towards precision nephrology. Genetic testing may be of value in this context but should not be used indiscriminately, but rather on the basis of a deep knowledge of IKDs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Benefits of Early versus Late Therapeutic Intervention in Fabry Disease

  • Furlano, Monica|||0000-0003-1025-3901
  • Ars, Elisabet|||0000-0002-4118-4358
  • Matamala Gastón, Ana María
  • Brossa Loidi, Vicens|||0000-0003-0403-6425
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Venegas, María del Prado|||0000-0001-9048-4501
  • Crespí, Jaume|||0000-0001-7564-2479
  • Roé Crespo, Esther|||0000-0003-1601-9227
  • Torra Balcells, Roser|||0000-0001-8714-2332
Fabry disease (FD) is an X-linked lysosomal storage disorder caused by pathogenic variants of the GLA gene. Heterozygous female patients may show much more variability in clinical manifestations, ranging from asymptomatic to full-blown disease. Because of this heterogeneous clinical picture in women, the diagnosis of FD has typically been delayed for more than a decade, and the optimal time to initiate treatment remains controversial. Case Presentation. Here, we present two unrelated female patients diagnosed with FD harbouring the same pathogenic GLA variant. We discuss the implications of initiating specific therapy at different stages of the disease, with and without organ involvement (early versus late therapeutic intervention). These clinical cases suggest that initiating specific treatment at an earlier age in women with FD may prevent organ involvement and associated clinical events.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Recomendaciones de manejo de la afectación renal en el complejo esclerosis tuberosa

  • Ariceta Iraola, Gema|||0000-0003-1763-1098
  • Buj Pradilla, María José
  • Furlano, Monica|||0000-0003-1025-3901
  • Martínez, V.
  • Matamala, Anna|||0000-0002-1607-9011
  • Morales, M.
  • Robles, N.R.
  • Sans, Laia
  • Villacampa, F.
  • Torra Balcells, Roser|||0000-0001-8714-2332
El complejo esclerosis tuberosa (CET) es una enfermedad rara, hereditaria, multisistémica y con un amplio espectro fenotípico. Su manejo requiere de la colaboración de múltiples especialistas. Así como en la edad pediátrica cobra un especial relieve el neurólogo pediatra, en la edad adulta la afectación renal es la causante de la mayor morbimortalidad. Existen diversas recomendaciones sobre el manejo general del paciente con CET, pero ninguna que se centre en la afectación renal. Las presentes recomendaciones responden a la necesidad de proporcionar pautas para facilitar un mejor conocimiento y manejo diagnóstico-terapéutico de la afectación renal del CET mediante un uso racional de las pruebas complementarias y el empleo correcto de los tratamientos disponibles. Su elaboración se ha basado en el consenso dentro del grupo de trabajo de enfermedades renales hereditarias de la SEN/REDINREN. Ha contado con la participación de especialistas en CET no nefrólogos también con el fin de ampliar la visión de la enfermedad.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease due to mutations in UMOD and MUC1

  • Olinger, Eric|||0000-0003-1178-7980
  • Hofmann, Patrick|||0000-0002-4586-641X
  • Kidd, Kendrah|||0000-0003-3771-0949
  • Dufour, Inès
  • Belge, Hendrica
  • Schaeffer, Céline|||0000-0001-5883-3951
  • Kipp, Anne
  • Bonny, Olivier
  • Deltas, Constantinos|||0000-0001-5549-9169
  • Demoulin, Nathalie|||0000-0002-3566-3950
  • Fehr, Thomas|||0000-0003-1668-1800
  • Fuster, D.G.|||0000-0001-7220-1803
  • Gale, Daniel|||0000-0002-9170-1579
  • Goffin, Eric|||0000-0001-9242-7148
  • Hodaňová, Kateřina|||0000-0001-9172-9945
  • Huynh-Do, Uyen|||0000-0002-7276-032X
  • Kistler, Andreas|||0000-0002-4114-9560
  • Morelle, Johann|||0000-0002-6925-1989
  • Papagregoriou, Gregory|||0000-0002-2440-9789
  • Pirson, Yves
  • Sandford, Richard
  • Sayer, John|||0000-0003-1881-3782
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Venzin, Christina
  • Venzin, Reto
  • Vogt, Bruno|||0000-0002-1548-6387
  • Živná, Martina
  • Greka, Anna|||0000-0001-5697-7791
  • Dahan, Karin
  • Rampoldi, Luca|||0000-0002-0544-7042
  • Kmoch, Stanislav
  • Bleyer, Anthony|||0000-0002-2804-5273
  • Devuyst, Olivier|||0000-0003-3744-4767
Autosomal dominant tubulointerstitial kidney disease (ADTKD) is an increasingly recognized cause of end-stage kidney disease, primarily due to mutations in UMOD and MUC1. The lack of clinical recognition and the small size of cohorts have slowed the understanding of disease ontology and development of diagnostic algorithms. We analyzed two registries from Europe and the United States to define genetic and clinical characteristics of ADTKD-UMOD and ADTKD-MUC1 and develop a practical score to guide genetic testing. Our study encompassed 726 patients from 585 families with a presumptive diagnosis of ADTKD along with clinical, biochemical, genetic and radiologic data. Collectively, 106 different UMOD mutations were detected in 216/562 (38.4%) of families with ADTKD (303 patients), and 4 different MUC1 mutations in 72/205 (35.1%) of the families that are UMOD-negative (83 patients). The median kidney survival was significantly shorter in patients with ADTKD-MUC1 compared to ADTKD-UMOD (46 vs. 54 years, respectively), whereas the median gout-free survival was dramatically reduced in patients with ADTKD-UMOD compared to ADTKD-MUC1 (30 vs. 67 years, respectively). In contrast to patients with ADTKD-UMOD, patients with ADTKD-MUC1 had normal urinary excretion of uromodulin and distribution of uromodulin in tubular cells. A diagnostic algorithm based on a simple score coupled with urinary uromodulin measurements separated patients with ADTKD-UMOD from those with ADTKD-MUC1 with a sensitivity of 94.1%, a specificity of 74.3% and a positive predictive value of 84.2% for a UMOD mutation. Thus, ADTKD-UMOD is more frequently diagnosed than ADTKD-MUC1, ADTKD subtypes present with distinct clinical features, and a simple score coupled with urine uromodulin measurements may help prioritizing genetic testing.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Integration-free induced pluripotent stem cells derived from a patient with autosomal recessive Alport syndrome (ARAS)

  • Kuebler, Bernd|||0000-0002-4472-871X
  • Aran, Begoña|||0000-0002-5011-7755
  • Miquel-Serra, Laia|||0000-0001-8382-3341
  • Muñoz, Yolanda
  • Ars, Elisabet|||0000-0002-4118-4358
  • Bullich Vilanova, Gemma|||0000-0002-0737-4422
  • Furlano, Monica|||0000-0003-1025-3901
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Martí, Mercè|||0000-0002-1846-0043
  • Veiga, Anna|||0000-0002-0943-9904
  • Raya, Ángel|||0000-0003-2189-9775
A skin biopsy was obtained from a 25-year-old female patient with autosomal recessive Alport syndrome (ARAS) with the homozygous COL4A3 mutation c.345delG, p.(P166Lfs*37). Dermal fibroblasts were derived and reprogrammed by nucleofection with episomal plasmids carrying OCT3/4, SOX2, KLF4 LIN28, L-MYC and p53shRNA. The generated induced Pluripotent Stem Cell (iPSC) clone AS FiPS1 Ep6F-2 was free of genomically integrated reprogramming genes, had the specific homozygous mutation, a stable karyotype, expressed pluripotency markers and generated embryoid bodies which were differentiated towards the three germ layers in vitro. This iPSC line offers a useful resource to study Alport syndrome pathomechanisms and drug testing.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A review on autosomal dominant tubulointerstitial kidney disease Revisión de la nefropatía tubulointersticial autosómica dominante

  • Ayasreh Fierro, Nadia|||0000-0001-6436-5621
  • Miquel Rodríguez, Rosa
  • Matamala Gastón, Ana María
  • Ars, Elisabet|||0000-0002-4118-4358
  • Torra Balcells, Roser|||0000-0001-8714-2332
In recent years there has been a reclassification of hereditary tubulointerstitial renal diseases. The old concepts of nephronoptisis or medullary cystic disease have been reordered based on the discovery of new genes. The 2015 KDIGO guidelines proposed a unification of terminology, diagnostic criteria and monitoring. So far 4 genes causing autosomal dominant tubulointerstitial kidney disease have been described: MUC1, UMOD, HNF1B and REN. Although the mutation in each of them causes distinctive features in how they present, all have in common the progressive tubulointerstitial damage and renal fibrosis. In this article, we present a review of the guidelines and the literature, and some practical recommendations for dealing with this disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Correction, The 2019 and 2021 International workshops on Alport syndrome

  • Daga, Sergio
  • Ding, Jie
  • Deltas, Constantinos|||0000-0001-5549-9169
  • Savige, Judy|||0000-0002-6813-0288
  • Lipska-Ziętkiewicz, Beata S.|||0000-0002-4169-9685
  • Hoefele, Julia|||0000-0002-7917-7129
  • Flinter, Frances
  • Gale, Daniel|||0000-0002-9170-1579
  • Aksenova, Marina|||0000-0002-3699-1884
  • Kai, Hirofumi
  • Perin, Laura
  • Barua, Moumita
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Miner, Jeff H.|||0000-0002-1510-8714
  • Massella, Laura|||0000-0001-5796-3965
  • Ljubanović, Danica Galešić
  • Lennon, Rachel|||0000-0001-6400-0227
  • Weinstock, Andrè B.
  • Knebelmann, Bertrand
  • Cerkauskaite, Agne
  • Gear, Susie
  • Gross, Oliver|||0000-0002-8390-8852
  • Turner, A. Neil|||0000-0003-4547-873X
  • Baldassarri, Margherita
  • Pinto, Anna Maria|||0000-0001-6259-6901
  • Renieri, Alessandra|||0000-0002-0846-9220